Media headlines about Vascular Biogenics (NASDAQ:VBLT) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vascular Biogenics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.9130713871985 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
VBLT has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Vascular Biogenics in a research note on Tuesday, November 21st. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Friday, November 24th. ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray Companies lowered shares of Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research note on Thursday, March 8th. Finally, JMP Securities lowered shares of Vascular Biogenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. Vascular Biogenics presently has a consensus rating of “Hold” and an average price target of $3.19.
Shares of Vascular Biogenics stock traded up $0.07 during mid-day trading on Monday, hitting $2.35. 364,699 shares of the stock traded hands, compared to its average volume of 436,853. Vascular Biogenics has a 12 month low of $2.20 and a 12 month high of $9.05. The stock has a market cap of $68.02, a price-to-earnings ratio of -6.35 and a beta of -2.44.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.19. The company had revenue of $13.86 million for the quarter. equities research analysts expect that Vascular Biogenics will post -0.79 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/19/vascular-biogenics-vblt-getting-somewhat-positive-press-coverage-analysis-shows.html.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.